Gregor K Wenning

List of Publications by Year
in descending order

253 papers	20,068 citations	12330 69 h-index	12272 133 g-index
280 all docs	280 docs citations	280 times ranked	13937 citing authors

#	Article	IF	Citations
1	MovementDisorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations TheMovementDisorder Society Task Force on rating scales for Parkinson's disease. Movement Disorders, 2004, 19, 1020-1028.	3.9	1,739
2	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
3	Consensus statement on the diagnosis of multiple system atrophy. Clinical Autonomic Research, 1998, 8, 359-362.	2.5	823
4	The diagnosis of Parkinson's disease. Lancet Neurology, The, 2006, 5, 75-86.	10.2	665
5	Multiple-System Atrophy. New England Journal of Medicine, 2015, 372, 249-263.	27.0	600
6	Tollâ€like receptor 4 is required for Î±â€synuclein dependent activation of microglia and astroglia. Glia, 2013, 61, 349-360.	4.9	542
7	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Movement Disorders, 2004, 19, 1391-1402.	3.9	481
8	Multiple system atrophy. Lancet Neurology, The, 2004, 3, 93-103.	10.2	443
9	The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurology, The, 2013, 12, 264-274.	10.2	426
10	Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders. Archives of Neurology, 2001, 58, 259.	4.5	375
11	How to diagnose dementia with Lewy bodies: State of the art. Movement Disorders, 2005, 20, S11-S20.	3.9	304
12	Multiple system atrophy: A primary oligodendrogliopathy. Annals of Neurology, 2008, 64, 239-246.	5.3	279
13	SNCA variants are associated with increased risk for multiple system atrophy. Annals of Neurology, 2009, 65, 610-614.	5.3	257
14	Toll-Like Receptor 4 Promotes Î±-Synuclein Clearance and Survival of Nigral Dopaminergic Neurons. American Journal of Pathology, 2011, 179, 954-963.	3.8	230
15	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders, 2022, 37, 1131-1148.	3.9	222
16	Red flags for multiple system atrophy. Movement Disorders, 2008, 23, 1093-1099.	3.9	215
17	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. Movement Disorders, 2010, 25, 2604-2612.	3.9	205
18	Iron in Neurodegeneration â€“ Cause or Consequence?. Frontiers in Neuroscience, 2019, 13, 180.	2.8	204

#	Article	IF	Citations
19	Microglial activation mediates neurodegeneration related to oligodendroglial Î±â€synucleinopathy: Implications for multiple system atrophy. Movement Disorders, 2007, 22, 2196-2203.	3.9	203
20	Premotor signs and symptoms of multiple system atrophy. Lancet Neurology, The, 2012, 11, 361-368.	10.2	201
21	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. Movement Disorders, 2014, 29, 857-867.	3.9	193
22	Oxidative Stress in Transgenic Mice with Oligodendroglial Î±-Synuclein Overexpression Replicates the Characteristic Neuropathology of Multiple System Atrophy. American Journal of Pathology, 2005, 166, 869-876.	3.8	191
23	Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS). Clinical Autonomic Research, 2018, 28, 355-362.	2.5	176
24	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	12.8	170
25	Glial dysfunction in the pathogenesis of Î±-synucleinopathies: emerging concepts. Acta Neuropathologica, 2011, 121, 675-693.	7.7	164
26	Minocycline 1â€year therapy in multipleâ€systemâ€atrophy: Effect on clinical symptoms and [¹¹C] (R)â€PK11195 PET (MEMSAâ€trial). Movement Disorders, 2010, 25, 97-107.	3.9	163
27	Grading of neuropathology in multiple system atrophy: Proposal for a novel scale. Movement Disorders, 2005, 20, S29-S36.	3.9	161
28	Glia and alpha-synuclein in neurodegeneration: A complex interaction. Neurobiology of Disease, 2016, 85, 262-274.	4.4	156
29	Voxelâ€based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Movement Disorders, 2003, 18, 1132-1138.	3.9	153
30	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. NeuroImage, 2004, 21, 1443-1451.	4.2	149
31	Progression of falls in postmortem-confirmed Parkinsonian disorders. Movement Disorders, 1999, 14, 947-950.	3.9	144
32	Brain perfusion scintigraphy with99mTc-HMPAO or99mTc-ECD and123I-Î²-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 320-325.	2.1	137
33	Prospective Differentiation of Multiple System Atrophy From Parkinson Disease, With and Without Autonomic Failure. Archives of Neurology, 2009, 66, 742-50.	4.5	133
34	Multiple system atrophy: insights into a rare and debilitating movement disorder. Nature Reviews Neurology, 2017, 13, 232-243.	10.1	128
35	Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG). Movement Disorders, 2006, 21, 179-186.	3.9	126
36	Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPET study using 123I-Î²-CIT and 123I-IBZM. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1410-1414.	2.1	125

#	Article	IF	Citations
37	Dorsolateral nigral hyperintensity on 3.0T susceptibilityâ€weighted imaging in neurodegenerative Parkinsonism. Movement Disorders, 2015, 30, 1068-1076.	3.9	125
38	Enteric nervous system Î±-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology, 2015, 85, 1761-1768.	1.1	121
39	Voxel-wise analysis of [123I]Î²-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain, 2005, 128, 1605-1612.	7.6	115
40	Survival in multiple system atrophy. Movement Disorders, 2008, 23, 294-296.	3.9	112
41	Progression of brain atrophy in multiple system atrophy. Journal of Neurology, 2007, 254, 191-196.	3.6	108
42	Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. Journal of Neurology, 2013, 260, 2212-2219.	3.6	106
43	Healthâ€related quality of life in multiple system atrophy. Movement Disorders, 2006, 21, 809-815.	3.9	102
44	A validation exercise on the new consensus criteria for multiple system atrophy. Movement Disorders, 2009, 24, 2272-2276.	3.9	100
45	Progression of putaminal degeneration in multiple system atrophy: A serial diffusion MR study. NeuroImage, 2006, 31, 240-245.	4.2	98
46	The role of ?-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathologica, 2005, 109, 129-140.	7.7	97
47	Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model. Neurotoxicity Research, 2012, 21, 393-404.	2.7	96
48	Diffusion weighted imaging best discriminates PD from MSAâ€P: A comparison with tilt table testing and heart MIBG scintigraphy. Movement Disorders, 2007, 22, 1771-1776.	3.9	92
49	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 145-152.	10.2	90
50	Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. Neurology, 2016, 86, 1242-1249.	1.1	89
51	Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. Clinical Neurophysiology, 2021, 132, 666-682.	1.5	88
52	Glial cell death induced by overexpression of Î±â€synuclein. Journal of Neuroscience Research, 2001, 65, 432-438.	2.9	87
53	Supine hypertension in Parkinsonâ€™s disease and multiple system atrophy. Clinical Autonomic Research, 2016, 26, 97-105.	2.5	87
54	Comparison of diffusionâ€weighted imaging and [¹²³I]IBZMâ€SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. Movement Disorders, 2004, 19, 1438-1445.	3.9	86

#	Article	IF	Citations
55	Recent developments in multiple system atrophy. Journal of Neurology, 2009, 256, 1791-1808.	3.6	86
56	Stridor in multiple system atrophy. Neurology, 2019, 93, 630-639.	1.1	86
57	Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). Archives of Neurology, 2011, 68, 223-30.	4.5	83
58	Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Experimental Neurology, 2008, 210, 421-427.	4.1	79
59	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2019, 18, 724-735.	10.2	79
60	Mitochondrial inhibitor 3â€nitroproprionic acid enhances oxidative modification of alphaâ€synuclein in a transgenic mouse model of multiple system atrophy. Journal of Neuroscience Research, 2009, 87, 2728-2739.	2.9	78
61	Animal models of multiple system atrophy. Trends in Neurosciences, 2005, 28, 501-506.	8.6	77
62	Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection. PLoS ONE, 2011, 6, e19808.	2.5	77
63	Milestones in atypical and secondary Parkinsonisms. Movement Disorders, 2011, 26, 1083-1095.	3.9	74
64	Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. Journal of Neural Transmission, 2017, 124, 1567-1605.	2.8	74
65	Multiple system atrophy. International Review of Neurobiology, 2019, 149, 137-192.	2.0	74
66	Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human Î±-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathologica, 2012, 124, 51-65.	7.7	73
67	Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal Î±-synucleinopathy. Molecular Neurodegeneration, 2017, 12, 52.	10.8	73
68	A critique of the second consensus criteria for multiple system atrophy. Movement Disorders, 2019, 34, 975-984.	3.9	73
69	Anle138b modulates Î±â€synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Movement Disorders, 2019, 34, 255-263.	3.9	72
70	Multiple system atrophy: An update. Movement Disorders, 2003, 18, 34-42.	3.9	71
71	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. Neurobiology of Disease, 2015, 80, 29-41.	4.4	71
72	Increased daytime sleepiness in Parkinson's disease: A questionnaire survey. Movement Disorders, 2003, 18, 319-323.	3.9	70

#	Article	IF	Citations
73	Cortical atrophy in the cerebellar variant of multiple system atrophy: A voxelâ€based morphometry study. Movement Disorders, 2006, 21, 159-165.	3.9	67
74	Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study. Movement Disorders, 2007, 22, 1138-1144.	3.9	66
75	Targeted overexpression of human Î±-synuclein in oligodendroglia induces lesions linked to MSA -like progressive autonomic failure. Experimental Neurology, 2010, 224, 459-464.	4.1	65
76	The reorganization of functional architecture in the early-stages of Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 61-68.	2.2	64
77	Topography of putaminal degeneration in multiple system atrophy: A diffusion magnetic resonance study. Movement Disorders, 2006, 21, 847-852.	3.9	62
78	Management of supine hypertension in patients with neurogenic orthostatic hypotension. Journal of Hypertension, 2019, 37, 1541-1546.	0.5	60
79	The â€œcold hands signâ€•in multiple system atrophy. Movement Disorders, 1997, 12, 514-518.	3.9	58
80	Progression of parkinsonism in multiple system atrophy. Journal of Neurology, 2005, 252, 91-96.	3.6	55
81	Animal models of multiple system atrophy. Clinical Autonomic Research, 2015, 25, 9-17.	2.5	55
82	Multiple system atrophy: pathogenic mechanisms and biomarkers. Journal of Neural Transmission, 2016, 123, 555-572.	2.8	55
83	Nonâ€Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. Annals of Neurology, 2020, 88, 712-722.	5.3	55
84	Multiple-System Atrophy. New England Journal of Medicine, 2015, 372, 1374-1376.	27.0	53
85	Simultaneous Intrastriatal 6-Hydroxydopamine and Quinolinic Acid Injection: A Model of Early-Stage Striatonigral Degeneration. Experimental Neurology, 2001, 167, 133-147.	4.1	51
86	Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 217	3.2	51
87	Bladder dysfunction in a transgenic mouse model of multiple system atrophy. Movement Disorders, 2013, 28, 347-355.	3.9	50
88	Progressive striatonigral degenerationÂin a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. Acta Neuropathologica Communications, 2018, 6, 2.	5.2	50
89	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. Parkinsonism and Related Disorders, 2018, 54, 90-94.	2.2	49
90	123I-Î²-CIT and123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Movement Disorders, 1998, 13, 438-445.	3.9	48

#	Article	IF	Citations
91	Olivopontocerebellar atrophy: Toward a better nosological definition. Movement Disorders, 2006, 21, 1607-1613.	3.9	48
92	Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness. Clinical Autonomic Research, 2021, 31, 369-384.	2.5	48
93	Detecting nocturnal hypertension in Parkinsonâ€™s disease and multiple system atrophy: proposal of a decision-support algorithm. Journal of Neurology, 2014, 261, 1291-1299.	3.6	47
94	The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint. Journal of Alzheimer's Disease, 2018, 61, 1253-1273.	2.6	47
95	Freezing of gait in postmortemâ€confirmed atypical parkinsonism. Movement Disorders, 2002, 17, 1041-1045.	3.9	46
96	Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: Experimental evidence. Experimental Neurology, 2013, 247, 531-536.	4.1	46
97	Brain structural profile of multiple system atrophy patients with cognitive impairment. Journal of Neural Transmission, 2017, 124, 293-302.	2.8	46
98	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. Parkinsonism and Related Disorders, 2018, 46, 47-55.	2.2	45
99	Placebo-Controlled Trial of Amantadine in Multiple-System Atrophy. Clinical Neuropharmacology, 2005, 28, 225-227.	0.7	44
100	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0189897.	2.5	44
101	Toward a primate model ofl-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. Movement Disorders, 2000, 15, 531-536.	3.9	43
102	Sensorâ€based gait analysis in atypical parkinsonian disorders. Brain and Behavior, 2018, 8, e00977.	2.2	43
103	Therapeutic strategies in multiple system atrophy. Movement Disorders, 2005, 20, S67-S76.	3.9	42
104	Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. NeuroReport, 2004, 15, 1711-1714.	1.2	40
105	The role of Î±-synuclein and tau in neurodegenerative movement disorders. Current Opinion in Neurology, 2005, 18, 357-362.	3.6	40
106	Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]Î²-CIT SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1012-1020.	6.4	40
107	Genetic players in multiple system atrophy: unfolding the nature of the beast. Neurobiology of Aging, 2011, 32, 1924.e5-1924.e14.	3.1	39
108	Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications. Neurotoxicity Research, 2015, 28, 185-194.	2.7	38

#	Article	IF	Citations
109	Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy. Sleep, 2018, 41, .	1.1	38
110	Tumor necrosis factor-?-induced cell death in U373 cells overexpressing ?-synuclein. Journal of Neuroscience Research, 2003, 73, 334-340.	2.9	37
111	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. Movement Disorders, 2019, 34, 1041-1048.	3.9	36
112	Towards translational therapies for multiple system atrophy. Progress in Neurobiology, 2014, 118, 19-35.	5.7	35
113	Management of Orthostatic Hypotension in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, S57-S64.	2.8	34
114	Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. Parkinsonism and Related Disorders, 2015, 21, 1393-1397.	2.2	33
115	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Journal of Neural Transmission, 2016, 123, 439-445.	2.8	32
116	Multiple system atrophy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 229-241.	1.8	31
117	Region-Specific Effects of Immunotherapy With Antibodies Targeting Î±-synuclein in a Transgenic Model of Synucleinopathy. Frontiers in Neuroscience, 2018, 12, 452.	2.8	31
118	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the ‹scp›Movement Disorder Society‹/scp› Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	1.5	31
119	Cognition in multiple system atrophy: a singleâ€¢center cohort study. Annals of Clinical and Translational Neurology, 2020, 7, 219-228.	3.7	31
120	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 301-309.	2.4	30
121	Gait and postural disorders in parkinsonism: a clinical approach. Journal of Neurology, 2020, 267, 3169-3176.	3.6	30
122	Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. Journal of Neuroscience Research, 2004, 78, 87-91.	2.9	28
123	Striatal transplantation for multiple system atrophy â€" Are grafts affected by Î±-synucleinopathy?. Experimental Neurology, 2009, 219, 368-371.	4.1	28
124	New insights into atypical parkinsonism. Current Opinion in Neurology, 2011, 24, 331-338.	3.6	27
125	A novel computer-assisted image analysis of [123I]Î²-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 702-710.	6.4	27
126	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 49, 81-87.	2.2	27

#	Article	IF	Citations
127	Validation of the Neurogenic Orthostatic Hypotension Ratio with Active Standing. Annals of Neurology, 2020, 88, 643-645.	5.3	27
128	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. Neuroscience Letters, 1999, 274, 61-65.	2.1	26
129	Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications. PLoS ONE, 2016, 11, e0150705.	2.5	26
130	The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent Î±-synuclein in experimental multiple system atrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 165513.	3.8	25
131	The Diagnostic Scope of Sensor-Based Gait Analysis in Atypical Parkinsonism: Further Observations. Frontiers in Neurology, 2019, 10, 5.	2.4	25
132	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. Neurology, 2020, 95, e2854-e2865.	1.1	25
133	Sex and age effects on cardiovascular autonomic function in healthy adults. Clinical Autonomic Research, 2015, 25, 317-326.	2.5	24
134	The Schellong test: detecting orthostatic blood pressure and heart rate changes in German-speaking countries. Clinical Autonomic Research, 2019, 29, 363-366.	2.5	24
135	Striatal transplantation in a rodent model of multiple system atrophy: Effects on Lâ€Ðopa response. Journal of Neuroscience Research, 2009, 87, 1679-1685.	2.9	23
136	Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. Frontiers in Neuroscience, 2016, 10, 99.	2.8	23
137	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology, 2018, 90, 74-82.	1.1	23
138	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. Parkinsonism and Related Disorders, 2019, 67, 60-65.	2.2	23
139	In vitro models of multiple system atrophy. Movement Disorders, 2005, 20, S53-S56.	3.9	22
140	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. Proteome Science, 2012, 10, 71.	1.7	22
141	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. Clinical Autonomic Research, 2021, 31, 157-164.	2.5	22
142	Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. Parkinsonism and Related Disorders, 2021, 86, 124-132.	2.2	22
143	Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness : Consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). Autonomic Neuroscience: Basic and Clinical, 2021, 233, 102792.	2.8	22
144	Early distinction of Parkinsonâ€variant multiple system atrophy from Parkinson's disease. Movement Disorders, 2019, 34, 440-441.	3.9	21

#	Article	IF	Citations
145	Intact Olfaction in a Mouse Model of Multiple System Atrophy. PLoS ONE, 2013, 8, e64625.	2.5	20
146	Multiple system atrophy: experimental models and reality. Acta Neuropathologica, 2018, 135, 33-47.	7.7	20
147	Cognitive impairment in multiple system atrophy. Movement Disorders, 2017, 32, 1338-1339.	3.9	19
148	Urinary retention discriminates multiple system atrophy from Parkinson's disease. Movement Disorders, 2019, 34, 1926-1928.	3.9	19
149	Gender differences in clinical, laboratory and polysomnographic features of restless legs syndrome. Journal of Sleep Research, 2020, 29, e12875.	3.2	19
150	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. Movement Disorders, 2012, 27, 1683-1685.	3.9	18
151	Multiple system atrophy as emerging template for accelerated drug discovery in Î±-synucleinopathies. Parkinsonism and Related Disorders, 2014, 20, 793-799.	2.2	18
152	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. Parkinsonism and Related Disorders, 2020, 77, 57-63.	2.2	18
153	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [<scp>¹¹C</scp>]<scp>PBR28</scp> and Machine Learning Analysis. Movement Disorders, 2022, 37, 119-129.	3.9	18
154	Characterization of gait variability in multiple system atrophy and Parkinsonâ€™s disease. Journal of Neurology, 2021, 268, 1770-1779.	3.6	18
155	Cortical and brain stem hyperexcitability in a pathologically confirmed case of multiple system atrophy. Movement Disorders, 2000, 15, 362-363.	3.9	17
156	Assessing disease progression with MRI in atypical parkinsonian disorders. Movement Disorders, 2009, 24, S699-702.	3.9	17
157	Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. Movement Disorders, 2011, 26, 507-515.	3.9	17
158	Involvement of Peripheral Nerves in the Transgenic PLP-Î±-Syn Model of Multiple System Atrophy: Extending the Phenotype. PLoS ONE, 2015, 10, e0136575.	2.5	17
159	Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. Neurotherapeutics, 2016, 13, 871-879.	4.4	17
160	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. Parkinsonism and Related Disorders, 2018, 56, 33-40.	2.2	17
161	Failure of Neuroprotection by Embryonic Striatal Grafts in a Double Lesion Rat Model of Striatonigral Degeneration (Multiple System Atrophy). Experimental Neurology, 2000, 164, 166-175.	4.1	16
162	Models of Multiple System Atrophy. Current Topics in Behavioral Neurosciences, 2013, 22, 369-393.	1.7	16

#	Article	IF	Citations
163	An update on the cerebellar subtype of multiple system atrophy. Cerebellum and Ataxias, 2014, 1, 14.	1.9	16
164	Is multiple system atrophy an infectious disease?. Annals of Neurology, 2018, 83, 10-12.	5.3	16
165	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. Parkinsonism and Related Disorders, 2019, 58, 23-27.	2.2	16
166	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. Parkinsonism and Related Disorders, 2021, 82, 87-91.	2.2	16
167	Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease. Movement Disorders, 2021, 36, 449-459.	3.9	16
168	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. Journal of Parkinson's Disease, 2019, 9, 681-691.	2.8	15
169	Automated Analysis of Diffusionâ€Weighted <scp>Magnetic Resonance Imaging</scp> for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. Movement Disorders, 2021, 36, 241-245.	3.9	15
170	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. Movement Disorders, 2016, 31, 1577-1581.	3.9	14
171	Distinct Parameters in the EEG of the PLP Î±-SYN Mouse Model for Multiple System Atrophy Reinforce Face Validity. Frontiers in Behavioral Neuroscience, 2017, 10, 252.	2.0	14
172	Autonomic function testing in Friedreichâ€™s ataxia. Journal of Neurology, 2018, 265, 2015-2022.	3.6	14
173	Emergent creativity in frontotemporal dementia. Journal of Neural Transmission, 2021, 128, 279-293.	2.8	14
174	Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy. Movement Disorders, 2007, 22, 353-358.	3.9	13
175	Autonomic function testing in spinocerebellar ataxia type 2. Clinical Autonomic Research, 2018, 28, 341-346.	2.5	13
176	Is Multiple System Atrophy a Prion-like Disorder?. International Journal of Molecular Sciences, 2021, 22, 10093.	4.1	12
177	Toll-like receptor 4 deficiency facilitates Î±-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease. Parkinsonism and Related Disorders, 2021, 91, 59-65.	2.2	12
178	Cognition in a multiple system atrophy series of cases from Argentina. Arquivos De Neuro-Psiquiatria, 2014, 72, 773-776.	0.8	11
179	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. Movement Disorders, 2017, 32, 1356-1364.	3.9	11
180	Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived Î±-synuclein in oligodendroglia: implications for MSA pathogenesis. BMC Neuroscience, 2018, 19, 32.	1.9	11

#	Article	IF	Citations
181	SYNE1-ataxia: Novel genotypic and phenotypic findings. Parkinsonism and Related Disorders, 2019, 62, 210-214.	2.2	11
182	High-salt diet does not boost neuroinflammation and neurodegeneration in a model of Î±-synucleinopathy. Journal of Neuroinflammation, 2020, 17, 35.	7.2	11
183	<scp>ATH434</scp> Reduces Î±â€Synucleinâ€Related Neurodegeneration in a Murine Model of Multiple System Atrophy. Movement Disorders, 2021, 36, 2605-2614.	3.9	11
184	Current experimental disease-modifying therapeutics for multiple system atrophy. Journal of Neural Transmission, 2021, 128, 1529-1543.	2.8	11
185	Behavioral and histological analysis of a partial doubleâ€lesion model of parkinsonâ€variant multiple system atrophy. Journal of Neuroscience Research, 2012, 90, 1284-1295.	2.9	10
186	Cardiovascular autonomic function testing in multiple system atrophy and Parkinsonâ€™s disease: an expert-based blinded evaluation. Clinical Autonomic Research, 2020, 30, 255-263.	2.5	10
187	Female sexual dysfunction in multiple system atrophy: a prospective cohort study. Clinical Autonomic Research, 2021, 31, 713-717.	2.5	10
188	Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?. Journal of Parkinson's Disease, 2022, 12, 1369-1387.	2.8	10
189	Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. Movement Disorders, 2016, 31, 235-240.	3.9	9
190	TNFÎ± inhibitors as targets for protective therapies in MSA: a viewpoint. Journal of Neuroinflammation, 2019, 16, 80.	7.2	9
191	Olfaction in patients with isolated REM sleep behavior disorder who eventually develop multiple system atrophy. Sleep, 2020, 43, .	1.1	9
192	Clinically probable multiple system atrophy with predominant parkinsonism associated with myotonic dystrophy type 2. Movement Disorders, 2009, 24, 1407-1409.	3.9	8
193	Signs of Chronic Hypoxia Suggest a Novel Pathophysiological Event in <scp>Î±â€Synucleinopathies</scp>. Movement Disorders, 2020, 35, 2333-2338.	3.9	8
194	Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. Parkinsonism and Related Disorders, 2021, 85, 30-36.	2.2	8
195	Sensitivity to Change and Patientâ€Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Dataâ€Driven Analysis. Movement Disorders, 2022, 37, 1425-1431.	3.9	8
196	An early report of striatonigral degeneration. Movement Disorders, 2000, 15, 159-162.	3.9	7
197	Multiple system atrophy masking multiple sclerosis. Clinical Neurology and Neurosurgery, 2010, 112, 59-61.	1.4	7
198	Do periodic arm movements during sleep exist in healthy subjects? A polysomnographic study. Sleep Medicine, 2014, 15, 1150-1154.	1.6	7

#	Article	IF	Citations
199	Laboratoryâ€Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the <scp>MoDiMSA Study Group</scp>. Movement Disorders Clinical Practice, 2021, 8, 322-340.	1.5	7
200	Cardiac sympathetic innervation in Parkinsonâ€™s disease versus multiple system atrophy. Clinical Autonomic Research, 2022, 32, 103-114.	2.5	7
201	Disease Progression in Multiple System Atrophyâ€”Novel Modeling Framework and Predictive Factors. Movement Disorders, 2022, 37, 1719-1727.	3.9	7
202	The diagnosis of multiple system atrophy. Journal of Neurology, 2006, 253, iii2-iii15.	3.6	6
203	Effects of self-administered cannabidiol in a patient with multiple system atrophy. Clinical Autonomic Research, 2020, 30, 355-356.	2.5	6
204	Neuropathology of multiple system atrophy: Kurt Jellinger`s legacy. Journal of Neural Transmission, 2021, 128, 1481-1494.	2.8	6
205	Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study. Movement Disorders Clinical Practice, 2021, 8, 1052-1060.	1.5	6
206	Autonomic failure: a neglected presentation of Parkinson's disease. Lancet Neurology, The, 2021, 20, 781-782.	10.2	6
207	Disproportionate antecollis: A warning sign for multiple system atrophy. Movement Disorders, 2007, 22, 1986-1986.	3.9	5
208	Overexpression of Î±-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity. BMC Neuroscience, 2015, 16, 86.	1.9	5
209	Overlaps between multiple system atrophy and multiple sclerosis: A novel perspective. Movement Disorders, 2016, 31, 1767-1771.	3.9	5
210	Cardiovascular autonomic testing in the work-up of cerebellar ataxia: insight from an observational single center study. Journal of Neurology, 2020, 267, 1097-1102.	3.6	5
211	Reliability and validity of Japanese version of Unified Multiple System Atrophy Rating Scale. Neurology and Clinical Neuroscience, 2021, 9, 171-180.	0.4	5
212	Instrumented gait analysis defines the walking signature of CACNA1A disorders. Journal of Neurology, 2022, 269, 2941-2947.	3.6	5
213	The role of cardiovascular autonomic failure in the differential diagnosis of Î±-synucleinopathies. Neurological Sciences, 2022, 43, 187-198.	1.9	5
214	Autonomic failure in CANVAS syndrome. Brain, 2014, 137, 2625-2626.	7.6	4
215	Very lateâ€onset pure autonomic failure. Movement Disorders, 2017, 32, 1106-1108.	3.9	4
216	Inhibition of the mammalian target or rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy. Clinical Autonomic Research, 2020, 30, 7-8.	2.5	4

#	Article	IF	Citations
217	Rifampicin for multiple system atrophy. Lancet Neurology, The, 2014, 13, 237-239.	10.2	3
218	Which way does the axis tip? IBD increases the risk of Parkinsonâ€™s disease. Gut, 2019, 68, 3-3.	12.1	3
219	The footprint of orthostatic hypotension in parkinsonian syndromes. Parkinsonism and Related Disorders, 2020, 77, 107-109.	2.2	3
220	Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders. European Journal of Neurology, 2022, 29, 2772-2780.	3.3	3
221	Bedside Assessment of Autonomic Dysfunction in Multiple System Atrophy. Journal of Parkinson's Disease, 2022, 12, 2277-2281.	2.8	3
222	Multiple system atrophy. , 2005, , 623-662.		2
223	Etiology, Pathology, and Pathogenesis. Blue Books of Neurology, 2010, 34, 321-339.	0.1	2
224	Modelling progressive autonomic failure in MSA: where are we now?. Journal of Neural Transmission, 2011, 118, 841-847.	2.8	2
225	Is Multiple System Atrophy a New Prion Disorder?. Movement Disorders, 2016, 31, 300-300.	3.9	2
226	Induced pluripotent stem cells in multiple system atrophy: recent developments and scientific challenges. Clinical Autonomic Research, 2019, 29, 385-395.	2.5	2
227	Is peripheral neuropathy a feature of multiple system atrophy?. Clinical Autonomic Research, 2001, 11, 63-63.	2.5	1
228	Parkinson-Plus Disorders. , 2008, , 157-175.		1
229	Corticobasal degeneration. , 0, , 75-98.		1
230	Parkinsonism â€“ other causes. , 0, , 99-125.		1
231	Multiple system atrophy â€“ Are cerebrospinal fluid cytokines reliable potential diagnostic marker?. Parkinsonism and Related Disorders, 2019, 65, 1-2.	2.2	1
232	Parkinsonism and dysautonomia: Multiple system atrophy?. Parkinsonism and Related Disorders, 2020, 77, 150-151.	2.2	1
233	Commentary: Discriminating Î±-synuclein strains in parkinson's disease and multiple system atrophy. Frontiers in Neuroscience, 2020, 14, 802.	2.8	1
234	Conjugal multiple system atrophy: Rethinking numbers of probability. Parkinsonism and Related Disorders, 2020, 77, 176-177.	2.2	1

#	Article	IF	Citations
235	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. Movement Disorders, 2021, 36, 2703-2705.	3.9	1
236	Autonomic History Taking and Key Symptoms: Where Is the Autonomic Disease?. , 2017, , 15-36.		1
237	No need to droop your head in Parkinson's disease?. Parkinsonism and Related Disorders, 2009, 15, 620.	2.2	0
238	Multiple system atrophy. , 0, , 1-15.		0
239	The differential diagnosis of parkinsonism: A clinical approach. , 2011, , 126-141.		0
240	Multiple System Atrophy (MSA). , 2013, , 2119-2141.		0
241	Magnetic resonance imaging of multiple system atrophy. , 0, , 167-203.		0
242	Multiple system atrophy in the USA: another piece in the jigsaw. Lancet Neurology, The, 2015, 14, 672-674.	10.2	0
243	Animal Models of Multiple-System Atrophy. , 2015, , 887-904.		0
244	Preface. Movement Disorders, 2016, 31, 151-151.	3.9	0
245	Which Autonomic Features Distinguish Multiple System Atrophy and When. Movement Disorders, 2020, 35, 902-903.	3.9	0
246	Cardiovascular autonomic failure in Parkinson's disease. International Review of Movement Disorders, 2021, 1, 119-146.	0.1	0
247	Kurt Jellinger, Doyen of international neuropathology. Journal of Neural Transmission, 2021, 128, 1479-1480.	2.8	0
248	Combination Lesion Models of MSA. Neuromethods, 2011, , 37-54.	0.3	0
249	Clinical Presentation. , 2014, , 97-119.		0
250	Multiple System Atrophy (MSA). , 2022, , 2409-2432.		0
251	Parkinson's disease and the spectrum of Lewy body disease. , 0, , 10-26.		0
252	Multiple system atrophy. , 0, , 27-57.		0

#	Article	IF	Citations
253	Non-pharmacological treatment for atypical parkinsonism. , 0, , 142-159.		0